Table 1.
Participant characteristics
| Characteristic | Presence of HLA-B*58:01 allele | P* | Total (n=2910) | |
|---|---|---|---|---|
| Positive (n=571) | Negative (n=2339) | |||
| Sex (No (%)) | ||||
| Male | 460 (80.6) | 1950 (83.4) | 0.11 | 2410 (82.8) |
| Female | 111 (19.4) | 389 (16.6) | 0.11 | 500 (17.2) |
| Age (years) | ||||
| Mean (range) | 54.8 (19-99) | 54.9 (14-95) | 0.86 | 54.9 (14-99) |
| Kidney function (No)† | ||||
| Renal insufficiency | 120 | 444 | 0.27 | 564 |
| Indication for allopurinol (No (%)) | ||||
| Chronic tophaceous gout | 204 (35.7) | 820 (35.1) | 0.76 | 1024 (35.2) |
| Hyperuricaemia | 141 (24.7) | 555 (23.7) | 0.63 | 696 (23.9) |
| Chronic tophaceous gout plus hyperuricaemia | 97 (17.0) | 371 (15.9) | 0.51 | 468 (16.1) |
| Chronic tophaceous gout plus other | 43 (7.5) | 173 (7.4) | 0.91 | 216 (7.4) |
| Other conditions‡ | 86 (15.1) | 420 (18.0) | 0.10 | 506 (17.4) |
*Comparison of clinical characteristics between HLA-B*58:01 positive and negative participants.
†Renal insufficiency was defined as greater than 1.3 mg/dL of serum creatinine.
‡Including urate nephropathy, prevention of recurrent nephrolithiasis, and prevention of recurrent calcium oxalate stones.